Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.

Distinguishing aggressive prostate cancer from indolent disease represents an important clinical challenge, because current therapy may lead to overtreatment of men with limited disease. The prostate-specific membrane antigen (PSMA) is a membrane-bound glycoprotein that is highly restricted to the prostate. Previously, studies analyzing the expression of PSMA have found an up-regulation in correlation with prostate cancer, particularly in advanced cancer. This association is ideal for an application as a prognostic marker. In the current study, we characterized PSMA expression in a high-risk cohort and evaluated its potential use as predictive marker of prostate-specific antigen (PSA) recurrence. PSMA expression was analyzed by immunohistochemistry using tissue microarrays composed of tumor samples from 450 patients. Protein intensity was recorded using a semiautomated quantitative microscope system (ACIS II; Clarient Chromavision Medical Systems, San Juan Capistrano, CA). PSMA expression levels differed significantly (P < .001) between benign prostatic tissue, localized prostate cancer, and lymph node metastases. Dividing the cohort into high- and low-PSMA expressing cancers based on the median area of positive staining, we found that high PSMA levels were associated with significant increase of PSA recurrence (P = .004). This was independent of clinical parameters such as lymph node tumor burden (lymph node density, >20%; P < .001), extraprostatic extension (P = .017), seminal vesicle invasion (P < .001), and high Gleason score (8-10, P = .006). In a multivariate model, PSMA expression and metastases to pelvic lymph nodes were significantly associated with time to PSA recurrence (HR, 1.4; 95% confidence interval, 1.1-2.8, P = .017; and hazard ratio, 5; 95% confidence interval, 2.6-9.7, P < .001, respectively). In summary, PSMA is independently associated with PSA recurrence in a high-risk cohort and thus might provide insight into the additional use of adjuvant therapy. Validation on other cohorts is required.

[1]  D. Gleason,et al.  Histologic grading of prostate cancer: a perspective. , 1992, Human pathology.

[2]  Debashis Ghosh,et al.  Decreased α-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death , 2005, Cancer Epidemiology Biomarkers & Prevention.

[3]  Gleason Df.  Classification of prostatic carcinomas. , 1966 .

[4]  U. Wetterauer,et al.  A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells , 2006, Cancer Immunology, Immunotherapy.

[5]  R. Cristiano,et al.  Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate , 2006, Gene Therapy.

[6]  D. Parekh,et al.  Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. , 2000, The Journal of urology.

[7]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[8]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[9]  P. Stattin.  Prognostic factors in prostate cancer. , 1997, Scandinavian journal of urology and nephrology. Supplementum.

[10]  Theodore L DeWeese,et al.  Pathological and molecular mechanisms of prostate carcinogenesis: Implications for diagnosis, detection, prevention, and treatment , 2004, Journal of cellular biochemistry.

[11]  D. Bostwick,et al.  Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma , 1998, Cancer.

[12]  G. Murphy,et al.  Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. , 1998, The Journal of urology.

[13]  S. Varambally,et al.  JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence , 2004, Cancer Research.

[14]  E. Holmes.  PSMA specific antibodies and their diagnostic and therapeutic use , 2001, Expert opinion on investigational drugs.

[15]  W. Fair,et al.  Expression of the prostate-specific membrane antigen. , 1994, Cancer research.

[16]  W. Catalona,et al.  Contemporary results of anatomic radical prostatectomy , 1999, CA: a cancer journal for clinicians.

[17]  D. Rimm,et al.  Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. , 2005, Journal of the National Cancer Institute.

[18]  S. Vallabhajosula,et al.  The utility of monoclonal antibodies in the imaging of prostate cancer. , 2002, Seminars in urologic oncology.

[19]  C. Sheehan,et al.  Prognostic markers inprostate cancer , 2002, Expert review of molecular diagnostics.

[20]  D. Ghosh,et al.  Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.

[21]  Paul J Maddon,et al.  Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen , 2006, Clinical Cancer Research.

[22]  M. Rubin,et al.  Prognostic factors in lymph node-positive prostate cancer. , 2005, Urology.

[23]  M. Cowen,et al.  Predicting life expectancy in men with clinically localized prostate cancer. , 2006, The Journal of urology.

[24]  David L Rimm,et al.  Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. , 2004, The American journal of pathology.

[25]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  J. Schalken.  Validation of molecular targets in prostate cancer , 2005, BJU international.

[28]  V. Reuter,et al.  Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. , 2001, Urology.